Biogen’s 2026 Q1: A Growth Playbook with an Acquisition Twist

Numbers at a glance

Biogen reported a first-quarter 2026 revenue of $2.5 billion, up about 2% year over year, a reminder that growth in biotech can be a patient’s patient game. GAAP diluted earnings per share (EPS) came in at $2.15, while the non-GAAP diluted EPS registered a robust $3.57, highlighting the usual spread between GAAP and non-GAAP views on profitability and operating performance.

The company’s product lineup continues to drive the earnings mix. Growth products delivered roughly 12% year-over-year growth. In-market performance included:

• LEQEMBI global revenue of $168 million, up 74% year over year, with U.S. in-market sales of about $86 million
• SKYCLARYS global revenue around $151 million
• ZURZUVAE revenue about $55 million
• VUMERITY global revenue near $179 million
• SPINRAZA global revenue of $374 million
• QALSODY global revenue of $33 million

Beyond the numbers, Biogen stresses progress across a broadened pipeline and new data readouts, which the company flags as supporting a continued trajectory in key segments.

Strategic moves: Apellis deal and Greater China rights

Two headline strategic actions sit at the center of Biogen’s current narrative. First, Biogen announced a proposed acquisition of Apellis Pharmaceuticals, framed as a strategic bet to bolster growth in immune-mediated retinal disease and nephrology. The company projects this transaction to be accretive to non-GAAP diluted EPS starting in 2027, with the potential to meaningfully lift Biogen’s EPS CAGR through the end of the decade. The closing remains subject to customary conditions and regulatory approvals, so the plan exists as a roadmap rather than a done deal.

Second, Biogen entered into an agreement with TJ Biopharma to acquire exclusive rights to felzartamab in the Greater China region, potentially unlocking one of the globe’s largest patient populations for IgA nephropathy. The deal underscores Biogen’s willingness to lean into international markets as a revenue engine and a means to diversify beyond its near-term growth products.

Guidance, optimism, and what it means for EPS consensus

Biogen updated its full-year 2026 guidance to reflect the continued strength of its business and ongoing investments for growth. The press release highlights revenue momentum and a favorable mix of products, but it also places emphasis on new data and strategic deals as levers for future performance. As with many earnings disclosures, readers will want to compare the reported EPS figures against EPS consensus estimates to gauge whether investors should expect a formal earnings surprise or a more modest deviation from expectations.

The combined effect of higher non-GAAP EPS guidance, the expected accretion from Apellis, and the potential lift from international licensing suggests a persistent push on the revenue forecast for Biogen, even if near-term growth rate remains a matter of product-level execution and market dynamics. The absence of an explicit earnings surprise label in the release means the market will likely rely on the 2026 revenue forecast, the trajectory of LEQEMBI and other growth assets, and the timing of deal integration to assess how Biogen’s earnings narrative evolves relative to street expectations.

What this portends for Biogen and its peers

Biogen’s quarterly results reinforce a few enduring themes in biotech investing: a diversified portfolio matters, strategic M&A can shift a company’s growth curve, and international expansion remains a meaningful catalyst for long-term revenue streams. The Apellis transaction, if completed, could reposition Biogen’s earnings power by broadening the addressable market and accelerating non-GAAP profitability, especially if the integration delivers a clean path to accretion by 2027.

For sector peers, the message is twofold. First, pipeline execution remains a market-differentiator; showing real-world data and durable demand for high-profile assets (like LEQEMBI) can support multiple expansion even in a crowded field. Second, regulatory and cross-border opportunities—evident in the Greater China deal—are becoming more central to growth strategies, particularly for companies with global ambitions but domestic revenue limitations.

Conclusion: A measured march forward with a headline-ready play

Biogen’s Q1 2026 results read as a disciplined reaffirmation of its growth path: steady top-line progression, meaningful EPS improvement on non-GAAP terms, and a pipeline-forward strategy that hinges on large-scale deals and international expansion. The company’s stock narrative will likely hinge on how quickly the Apellis transaction closes, how effectively Biogen can integrate new acquisitions without diluting core profitability, and how the 2026 revenue forecast translates into mid-cycle growth through the remainder of the decade. In the biotech cosmos, that is a plotline worth watching—seasoned, if not flashy, and well-suited to investors who prefer path dependence to fireworks.